비스포스포네이트 제제 관련 관절통 및 근육통에 대한 지역 약국 약사 및 환자 능동적 모니터링
Arthralgia and Myalgia Associated with the Use of Bisphosphonate: An Active Monitoring Study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: We investigated arthralgia and myalgia associated with the use of oral bisphosphonate (BP) by conducting a survey ofpatient. Methods: The pharmacists conducted a survey between 1 Oct 2019 and 30 Sep 2020 among patients who were dispensed BPin community pharmacies to assess their demographic and medical characteristics, and their experiences with, and process for pain. Logistic regression analyses were performed to find the risk factors associated with the pain, and the odds ratios (OR) and 95%confidence intervals (CI) were determined. Results: A total of 160 patients who used BP participated in the survey (74 [46.3%] usedrisedronate; 61 [38.1%] used alendronate; 23 [14.4%] used ibandronate), and 20 (12.5%) of them experienced pain. Significantstatistical differences of the characteristics between patients who experienced pain or not were observed regarding menopause, andparity. Compared with women who had one or two parity, women who had more than three parity were associated with the decreasedrisk of pain (OR, 0.24; 95% CI, 0.04-0.98). Moreover, steady exercise was associated with the decreased risk of pain compared toless exercise (OR, 0.37; 95% CI, 0.14-0.98). Conclusion: Our findings suggest that the risk of pain in BP-treated patients might bedifferent regarding the different ingredients of BP, and dosing frequency. This survey highlights a need for a further safety research tounderstand the factors influencing the pain associated with the BP treatment.
Abstract
Objective: We investigated arthralgia and myalgia associated with the use of oral bisphosphonate (BP) by conducting a survey ofpatient. Methods: The pharmacists conducted a survey between 1 Oct 2019 and 30 Sep 2020 among patients who were dispensed BPin community pharmacies to assess their demographic and medical characteristics, and their experiences with, and process for pain. Logistic regression analyses were performed to find the risk factors associated with the pain, and the odds ratios (OR) and 95%confidence intervals (CI) were determined. Results: A total of 160 patients who used BP participated in the survey (74 [46.3%] usedrisedronate; 61 [38.1%] used alendronate; 23 [14.4%] used ibandronate), and 20 (12.5%) of them experienced pain. Significantstatistical differences of the characteristics between patients who experienced pain or not were observed regarding menopause, andparity. Compared with women who had one or two parity, women who had more than three parity were associated with the decreasedrisk of pain (OR, 0.24; 95% CI, 0.04-0.98). Moreover, steady exercise was associated with the decreased risk of pain compared toless exercise (OR, 0.37; 95% CI, 0.14-0.98). Conclusion: Our findings suggest that the risk of pain in BP-treated patients might bedifferent regarding the different ingredients of BP, and dosing frequency. This survey highlights a need for a further safety research tounderstand the factors influencing the pain associated with the BP treatment.
참고문헌 (29)
- "Disease information - osteoporosis"[URL]
- 이종석, "국민건강영양조사(2008-2011)를 활용한 골다공증 진단을 위한 정상 참고치와 유병률 연구", 통계연구, 18(2), pp.42~65 (2013), 통계청
- "Statistics of national disease - osteoporosis"[URL]
- 전성욱, "골다공증의 약물치료", 대한의사협회지, 62(10), pp.542~550 (2019), 대한의사협회
- "Bisphosphonate"[URL]
- Choi HJ, "Treatment for osteoporosis : focusing for bisphosphonate therapy", Korean J Fam Pract, 3(1), pp.16~24 (2013)
- Wysowski DK, "Alendronate and risedronate: reports of severe bone, joint, and muscle pain", Arch Intern Med, 165(3), pp.346~347 (2005)
- "Severe musculoskeletal pain a risk with bisphosphonates"[URL]
- Thie´baud D, "An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates", Calcif Tissue Int, 61(1), pp.386~392 (1997)
- Uğurlar M, "Alendronate-and risedronate-induced acute polyarthritis", Osteoporos Int, 27(1), pp.3383~3385 (2016)
- Kang MK, "A study of adverse drug event reporting systems in Korea", Korean J Community Pharm, 5(1), pp.56~65 (2019)
- "Regional drug safety center information"[URL]
- "Regional drug safety center information and history"[URL]
- Jin XM, "The role of consumers in the spontaneous adverse drug events reporting", J Pharmacoepidemiol Risk Manag, 3(3), pp.101~112 (2010)
- Kang DY, "The active pharmacovigilance system : a postscript of visiting the harvard pilgrim health care institute", J Pharmacoepidemiol Risk Manag, 9, pp.45~47 (2017)
- Gordis L, "Epidemiology", pp.198~199 (2014), Elsevier
- Mor A, "Drug-induced arthritic and connective tissue disorders", Semin Arthritis Rheum, 38(3), pp.249~264 (2008)
- Adwan MH, "An update on drug-induced arthritis", Rheumatology International, 36(1), pp.1089~1097 (2016)
- Bannwarth B, "Drug-Induced Musculoskeletal Disorders", Drug Saf, 30(1), pp.27~46 (2007)
- Lewiecki EM, "Bisphosphonates for the treatment of osteoporosis : insights for clinicians", Ther Adv Chronic Dis, 1(3), pp.115~128 (2010)
- Lee J, "Public awareness of adverse drug reactions and pharmacovigilance system in Korea", J Pharmacoepidemiol Risk Manag, 5(2), pp.68~77 (2012)
- "Alendronate"[URL]
- "Change order for drug permission (bisphosphonate)"[URL]
- Bock O, "Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention", J Musculoskelet Neuronal Interact, 7(2), pp.144~148 (2007)
- 김지애, "Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data", Journal of Korean Medical Science, 32(5), pp.718~728 (2017), 대한의학회
- 김승현, "소아청소년 통증 평가를 위한 픽토그램 디자인 연구", Journal of Integrated Design Research, 18(4), pp.115~129 (2019), 디자인연구소[DOI]
- Hazell L, "Under-reporting of adverse drug reactions", Drug Saf, 29(5), pp.385~396 (2006)
- Rothman ML, "Patient-reported outcomes : conceptual issues", Value Health, 10(Suppl 2), pp.S66~S75 (2007)
- Schmier JK, "Patient recall and recall bias of health state and health status", Expert Rev Pharmacoecon Outcomes Res, 4(2), pp.159~163 (2004)